"This sets a new benchmark of survival for patients with inoperable stage III NSCLC treated with chemoradiation," said principal investigator Jeffrey D. Bradley, MD, Professor of Radiation Oncology and Director of the S. L. King Center for Proton Therapy at the Washington University School ...
[7]LuS, WuL, ZhangW, et al. Perioperative toripalimab+platinum-doublet chemotherapy vs chemotherapy in resectable stage Ⅱ/Ⅲ non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase...
[4]Villano JL, et al. Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol. 2015 Jan;17(1):122-8. [5]Patil T, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-...
[7]LuS, WuL, ZhangW, et al. Perioperative toripalimab+platinum-doublet chemotherapy vs chemotherapy in resectable stage Ⅱ/Ⅲ non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase Ⅲ Neotorch study[J]. J Clin Oncol, 2023, 41(36Suppl): 425126-4251...
The primary end point of overall survival improvement has been reached in the phase 3 LUNAR study, which is evaluating Tumor Treating Fields in combination with standard therapies for the treatment of stage IV non–small cell lung cancer.
frequently associated with tumor recurrence. Perioperative platinum-based chemotherapy is associated with a survival rate that is only 5.4% higher than that with surgery alone [3]. Even after curative resection, ~60% of patients with stage IIIA disease still develop recurrence after 3 years [4]....
Hellmann等人发现在高肿瘤突变负荷的NSCLC病人中(每兆碱基中突变基因数大于10个)联合使用nivolumab和Ipilimumab比单独使用化疗药物具有更长的无进展生存期(progression-free survival, PFS)。 在第二项研究中,研究人员招募了Stage IV期或者复发且未接受过化疗的NSCLC患者,按照1:1:1的比例分为nivolumab和Ipilimumab联合治疗...
[1]:一项Ⅲ期随机对照临床研究, 共纳入878例复发性或晚期非鳞NSCLC患者,数据显示, 卡铂+紫杉醇联合贝伐珠单抗一线治疗比较单纯化疗方案可明显延长患者生存时间 (中位OS 12.3个月 vs 10.3个月,HR=0.79,P=0.003;中位PFS 6.2个月 vs 4.5个月,HR=0.66,P<0.001),提高客观缓解率(objective response rate,ORR)(35...
经多因素分析结果提示,患者PFS获益与患者在治疗前4个月是否出现过治疗中断无明显相关性[9],周彩存教授补充道,根据MARIPOSA研究公布的最新数据,当患者接受4个月以上治疗后,即便患者曾在治疗前4个月因AE导致治疗中断,不仅不会对其PFS、客观缓解...
survival was equivalent among all three arms.673 IFCT 0002, a randomized trial, found no difference in 3-year overall survival (67.4% vs. 67.7%) with preoperative versus postoperative chemotherapy in patients with early-stag...